Status:
COMPLETED
Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis
Lead Sponsor:
Prince of Songkla University
Conditions:
Quality of Life
Respiratory Function Tests
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis
Detailed Description
A randomized, double blinded, placebo controlled study was conducted to evaluate the effects of a 12-week administration of roxithromycin 300 mg once daily and a 12-week follow-up period in symptomati...
Eligibility Criteria
Inclusion
- minimum 15 year maximum 75 years
- Criteria inclusion Criteria:
- Symptomatic bronchiectasis Stable clinical bronchiectasis
- Exclusion Criteria:
- Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung function tests Females who were lactating
Exclusion
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04122040
Start Date
March 1 2011
End Date
September 30 2011
Last Update
October 14 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.